Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.
What are the Ovaries?
The ovaries are a pair of organs in the female reproductive system that produce eggs and female hormones.
The Advanced Research Projects Agency for Health (ARPA-H) has awarded $45 million to rapidly develop sense-and-respond implant technology that could slash U.S. cancer-related deaths by more than 50%.
Researchers explore the involvement and altered expression of BBOX1-AS1 and microRNA-19b in polycystic ovary syndrome.
This study identifies links between exposure to chemicals like PFAS, parabens, and phenols and increased cancer risk, particularly among women and across racial groups. The findings spotlight the role of environmental toxins in hormone-related cancers, suggesting new avenues for cancer prevention and mitigation strategies.
An international clinical trial exploring a new way to treat rare and aggressive gynaecological cancers has launched in Melbourne.
A comprehensive review in Signal Transduction and Targeted Therapy delves into the versatility and effectiveness of mRNA vaccines, from their game-changing role in COVID-19 to potential applications in cancer and rare diseases. Despite drawbacks like stability and high immunogenicity, advancements in vaccine technology have poised mRNA platforms as a robust tool for both preventive and therapeutic interventions.
A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.
Today, the American Association for Cancer Research (AACR) released the 13th edition of its annual Cancer Progress Report, which chronicles how basic, translational, and clinical cancer research and cancer-related population sciences-;primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)-;remain vitally important to improving health and saving lives.
Increasing concerns regarding potentially harmful long-term effects of premenopausal bilateral oophorectomy (PBO) have caused a decline in the number of women choosing to proactively remove both ovaries as a precaution to protect against ovarian cancer.
Advanced research is casting light on possible early life factors – including poverty, physical or mental abuse – that may impact the rate of egg loss and increase the risk of cardiovascular disease in post-menopausal women.
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, today revealed new nationwide survey results indicating widespread confusion and misconceptions about ovarian cancer screening among a majority of women.
For the 314,000 people diagnosed with ovarian cancer each year, hope often comes in the form of platinum-based drugs such as cisplatin.
There's been a striking 79% increase in new cases of cancer among the under 50s around the world over the past three decades (1990-2019), finds research published today in the open access journal BMJ Oncology.
BRCA1 and BRCA2 are well-known breast cancer genes associated with a significantly increased risk of hereditary breast and ovarian cancer. However, there are an additional eleven genes associated with elevated risk for these types of cancer.
Recently published preclinical data by City of Hope scientists shows the immunotherapy is effective. Advanced ovarian cancer patients are now being enrolled in a Phase 1 first-in-human trial.
Researchers performed proteomic Mendelian randomization as well as co-localization analyses to identify drug targets for ovarian cancer.
CAR-T immune therapies could be effective against solid tumors if the right targets are identified, a new study led by University of Illinois Urbana-Champaign researchers suggests.
U.S. News & World Report ranks UCSF Health adult care among nation's top 10 hospitals in 7 specialties, Best in the West for neurology/neurosurgery and rheumatology.
Birmingham's Pepper Place has a striking new addition to its teeming farmers' market and noted food offerings -; a multimillion-dollar cancer research laboratory.
Deanna Denham Hughes was stunned when she was diagnosed with ovarian cancer last year. She was only 32. She had no family history of cancer, and tests found no genetic link. Hughes wondered why she, an otherwise healthy Black mother of two, would develop a malignancy known as a "silent killer."
A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working.